Pharvaris (NASDAQ:PHVS) Stock Price Up 8%

Pharvaris (NASDAQ:PHVS) shares rose 8% during trading on Monday . The company traded as high as $20.69 and last traded at $20.69. Approximately 23,719 shares traded hands during trading, a decline of 77% from the average daily volume of 103,124 shares. The stock had previously closed at $19.16.

Analysts Set New Price Targets

PHVS has been the topic of a number of analyst reports. JMP Securities upped their target price on Pharvaris from $49.00 to $50.00 and gave the company a “market outperform” rating in a research note on Thursday, April 11th. Morgan Stanley reissued an “overweight” rating and issued a $34.00 price objective on shares of Pharvaris in a research note on Monday. Finally, Wedbush reissued an “outperform” rating and issued a $35.00 price objective on shares of Pharvaris in a research note on Thursday, April 11th.

Pharvaris Stock Up 2.0 %

The company has a 50 day moving average of $23.73 and a two-hundred day moving average of $23.34.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP purchased a new stake in shares of Pharvaris during the third quarter worth $812,000. Walleye Capital LLC increased its position in shares of Pharvaris by 15.2% during the third quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock worth $1,691,000 after acquiring an additional 10,691 shares during the period. Blackstone Inc. purchased a new stake in shares of Pharvaris during the fourth quarter worth $2,805,000. venBio Partners LLC increased its position in shares of Pharvaris by 15.4% during the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock worth $137,992,000 after acquiring an additional 654,832 shares during the period. Finally, Commodore Capital LP purchased a new stake in shares of Pharvaris during the fourth quarter worth $22,440,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).